Fig. 17
From: In-silico molecular design of heterocyclic benzimidazole scaffolds as prospective anticancer agents
![Fig. 17](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13065-019-0608-5/MediaObjects/13065_2019_608_Fig17_HTML.png)
Binding mode of five most active compounds (16, 12, N9, W20 and Z24) into the 3ERT active site
From: In-silico molecular design of heterocyclic benzimidazole scaffolds as prospective anticancer agents
Binding mode of five most active compounds (16, 12, N9, W20 and Z24) into the 3ERT active site